Nuvectis Pharma, Inc.
NASDAQ:NVCTBiotechnology
+$0.39 today
- Market cap
- $697.75M
- Beta
- -0.07
- P/E (TTM)
- -11.2
- EPS (TTM)
- -$1.16
Volume 0.19M
Average 0.08M
NVCT Total Current Assets
All assets expected to be converted to cash or used up within one year.
Nuvectis Pharma, Inc.NASDAQ: NVCT
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets falls 15.8% from a year ago
Total current assets stood at $25.4M at the end of Q1 FY2026, down 15.8% from a year earlier and down 19.9% from the prior quarter. Over 3 fiscal years it compounded at +15.8% a year.
Context
- Total current assets amounted to 100.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Total current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps falling in the next quarterly balance sheet after a -15.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 31.71M USD
- Year-over-year change
- +70.4%
- 4-year CAGR
- +52.7%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.71M | +70.4% |
| FY2024 | 2024-12-31 | 18.61M | -3.0% |
| FY2023 | 2023-12-31 | 19.19M | -6.0% |
| FY2022 | 2022-12-31 | 20.41M | +249.8% |
| FY2021 | 2021-12-31 | 5.83M | — |
Total Current Assets vs competitors
How NVCT compares with its peers on the latest reported figures
- NVCT's Mar 2026 total current assets of $25.4M is the lowest of the 11 companies compared; the peer median is $246.57M.
- Its year-over-year change of -15.8% is the 10th highest of 11, against a peer median of +26.9%.
- Total current assets amounts to 100.0% of total assets for NVCT, versus a peer median of 95.8%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $161.41B | +422369.0% | +17.5% | 75.1% | |
| Mar 2026 | $1B | -2.1% | +43.2% | 97.5% | |
| Jun 2026 | $726.43M | +16.6% | -5.0% | 97.6% | |
| Mar 2026 | $471.18M | -14.1% | +2.5% | 99.7% | |
| Mar 2026 | $290.23M | +37.3% | +11.1% | 66.5% | |
| Mar 2026 | $202.9M | +62.7% | +34.0% | 89.1% | |
| Mar 2026 | $195.69M | +57.6% | +2.5% | 95.4% | |
| Mar 2026 | $182.52M | +0.2% | -0.3% | 83.8% | |
| Mar 2026 | $92.27M | +449.9% | +89.4% | 96.3% | |
| Mar 2026 | $40.03M | -40.2% | -15.7% | 98.6% | |
| Mar 2026 | $25.4M | -15.8% | +15.8% | 100.0% | |
| Peer median (excluding NVCT) | $246.57M | +26.9% | +6.8% | 95.8% | |
Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Nuvectis Pharma, Inc.
NASDAQ:NVCT
Intrinsic Alpha fair value
Locked
Current Price
$20.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.